Dr Frances Wells Neely, PHD | |
40043 97th St W, Leona Valley, CA 93551-7321 | |
(661) 916-9367 | |
Not Available |
Full Name | Dr Frances Wells Neely |
---|---|
Gender | Female |
Speciality | Psychologist - Clinical |
Location | 40043 97th St W, Leona Valley, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1417346958 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC0700X | Psychologist - Clinical | PSY 7266 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Frances Wells Neely, PHD 40043 97th St W, Leona Valley, CA 93551-7321 Ph: (661) 916-9367 | Dr Frances Wells Neely, PHD 40043 97th St W, Leona Valley, CA 93551-7321 Ph: (661) 916-9367 |
News Archive
A precedent-setting study published in the New England Journal of Medicine on Thursday, August 19 demonstrates definitively that early referrals to palliative care prolongs life for patients living with metastatic lung cancer.
For some, the disease multiple sclerosis attacks its victims slowly and progressively over a period of many years. For others, it strikes without warning in fits and starts. But all patients share one thing in common: the disease had long been present in their nervous systems, hiding under the radar from even the most sophisticated detection methods. But now, scientists at the Gladstone Institutes have devised a new molecular sensor that can detect MS at its earliest stages-even before the onset of physical signs.
Consumer-driven health plans can help employers reduce health care costs but might lead some patients to forgo necessary care to save money, according to a study by RAND, the Washington Post reports.
Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.
A recent study examined the ability of SARS-CoV-2 to impact DNA damage response and telomere stability in Vero E6 cells.
› Verified 8 days ago